Allergan

Allergan is a pharmaceutical company known for its innovative products in aesthetics, notably Botox. The company focuses on developing, manufacturing, and marketing a range of transformative medicines in a variety of therapeutic areas.

CCI Score

0.49

April 18

Latest Event

Unions and Advocacy Groups Criticize Proposed AbbVie-Allergan Merger

Consumer advocacy groups and unions, including Public Citizen and the American Federation of Teachers, have urged the Federal Trade Commission to reconsider the $63 billion AbbVie acquisition of Allergan, citing concerns over potential reductions in competition, worker rights, and corporate accountability.

Take Action

So what can you do? Support by shopping, spreading the word, or offering your support.

Shop Alternatives SEE ALL: Almirall

Kaken

Novo Nordisk
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

OBJECTOR

Allergan is currently rated as an Objector.

0 to +9 CCI Score

These companies deliberately avoid direct involvement with authoritarian practices. While they do not actively challenge oppressive regimes, they maintain a neutral stance to ensure they are not complicit in supporting such systems.

Latest Events

OCT

01

2023

Unions and Advocacy Groups Criticize Proposed AbbVie-Allergan Merger
-59.00

Consumer advocacy groups and unions, including Public Citizen and the American Federation of Teachers, have urged the Federal Trade Commission to reconsider the $63 billion AbbVie acquisition of Allergan, citing concerns over potential reductions in competition, worker rights, and corporate accountability.
-60

Business Practices and Ethical Responsibility

March 31

The merger is being criticized by unions and consumer groups for potentially undermining Allergan's commitment to responsible business practices and worker protections. Such a consolidation may prioritize profit over ethical responsibilities, leading to adverse impacts on labor standards and community well-being.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan
-80

Economic and Structural Influence

March 31

A proposed $63 billion merger raises significant concerns in terms of economic and structural influence. The consolidation could lead to increased market concentration and undermine regulatory oversight, potentially harming workers' rights and broader societal equity by amplifying corporate power.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan
DEC

11

2021

Allergan Settles $200M Opioid Crisis Lawsuit
28.60

Allergan Finance LLC agreed to pay $200 million to New York state and two counties to settle a lawsuit related to its involvement in the opioid crisis. As part of the agreement, it discontinued its branded prescription opioid business without admitting liability.
+40

Business Practices and Ethical Responsibility

March 31

The settlement, while not an admission of liability, represents a corrective corporate action to mitigate further harm from its opioid business. By discontinuing its branded prescription opioid operations and addressing opioid-related issues through a financial settlement, Allergan demonstrates a degree of accountability that can help protect affected communities. This action, although initiated under legal pressure, can be interpreted as a move towards ethical responsibility, aligning with progressive goals of corporate accountability.

USA: Pharmaceutical company Allergan reaches $200 million settlement with State of New York, removing it from ongoing lawsuit over the opioid crisis
MAR

01

2021

Allergan Settles Opioid Lawsuit with NY and Receives Lobbying Ban
52.90

Allergan has reached an agreement with New York Attorney General Letitia James to resolve claims related to its role in the opioid crisis. Under the settlement, the company may pay up to $200 million—with more than $150 million directed to opioid abatement—and is prohibited from engaging in lobbying activities about opioids or opioid products. The agreement also bars Allergan from using third parties to circumvent these restrictions.
+80

Political Contributions and Lobbying Efforts

March 31

The settlement includes a robust prohibition on lobbying and political influence regarding opioids, effectively curtailing Allergan's ability to interfere with public policy related to a critical health crisis. This enforced restriction is a positive development from an anti-fascist and progressive perspective, as it limits corporate influence over government policy and promotes accountability for past harmful practices.

Attorney General James Delivers Up to $200 Million to Help New York Combat Opioid Crisis, Allergan Agrees Not to Sell Opioids
FEB

20

2020

Allergan-AbbVie Merger Faces Opposition from Unions and Consumer Groups
-20.55

Consumer groups, including prominent unions and advocacy organizations, have petitioned the FTC to block the $63 billion merger between Allergan and AbbVie over concerns that it will create a monopoly and stifle competition. The petition also criticizes the companies' divestiture of assets as an insufficient remedy to restore competitive balance in the market.
-30

Business Practices and Ethical Responsibility

March 31

The merger is viewed as part of a trend toward corporate consolidation that risks undermining ethical business practices. The decision to proceed with the merger despite known market domination issues indicates a disregard for long‑term competitive health and consumer welfare, with divestitures seen as only a partial fix.

Consumer Groups, Unions Petition to Block Merger of Allergan and AbbVie
-40

Economic and Structural Influence

March 31

The merger is expected to restructure market dynamics significantly, increasing economic concentration and corporate power. This could lead to exclusionary practices and diminished competition in the pharmaceutical industry, a move that is concerning from an anti-authoritarian and pro-consumer perspective.

Consumer Groups, Unions Petition to Block Merger of Allergan and AbbVie